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Summary. The objective of the present study has been
to advance knowledge of the gastric role played by the
amino acid L-Arginine (L-Arg) in the evolution of a
chronic gastric ulcer. In order to clarify it, L-Arg alone
or together with Ibuprofen have been administrated in an
experimental acetic acid chronic ulcer, analysing
characteristic parameters of an active curative process,
such as PGE2 production, COX expression, and also
angiogenesis, proliferation/apoptosis and growth factors
expression. Our results reveal that L-Arg is favourable in
the healing process improving the curative course.
Ibuprofen caused a delay in ulcer healing, more evident
14 days after ulcer induction; COX-2 expression was
increased at the 7th day although no signal of protein
could be detected after 14 days; PGE2 production was
inhibited in intact and ulcerated areas at both times
assayed. In contrast, treatment with L-Arg reduced the
delay of the lesion, the increment in COX-2 expression
induced by Ibuprofen, and was able to maintain PGE2
levels similar to the control group after 14 days.
Additionally, the histological study showed that the
healing effects of L-Arg might be associated with an
increased angiogenesis and FGF-2 expression. These
actions could be considered key factors in the healing
response associated with L-Arg administration.
However, the proliferation study assayed with the
PCNA-immunostaining method did not reveal
significant differences, as the same as the apoptosis
analysis. In conclusion, the coupling of L-Arg to
Ibuprofen is an attractive alternative to Ibuprofen
administration alone because it not only attenuates but
also improves the evolution of chronic lesions through
mechanisms that implicate endogenous PG and FGF-2-
associated pathways, which allow an increase of
angiogenesis process. 
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Introduction
Nonsteroidal anti-inflammatory drug (NSAID)
causes damage in the gastric mucosa and impairment of
ulcer healing as unwanted side effects. Although the
inhibition of cyclooxygenase (COX), leading to
depletion of endogenous prostaglandins (PGs), is a
major pathogenic factor, it is unlikely that PGs
deficiency alone is sufficient to initiate the process that
ultimately results in gastric ulceration. Direct
cytotoxicity of NSAIDs may be involved in NSAID-
induced gastric lesions (Tomisato et al., 2004). The
introduction of highly selective COX-2 inhibitors or the
coprescriptions of gastroprotective agents with
nonselective NSAIDs have offered strategies to reduce
the incidence of gastroduodenal ulceration (James and
Hawkey, 2003). However, different data with selective
COX-2 inhibitors have shown that they can cause, in
some experimental conditions, rates of gastric lesion
comparable to those seen with traditional NSAIDs
including the delay of chronic gastric ulcers (Berenguer
et al., 2002; Villegas et al., 2002).
Other strategies for developing NSAID that spare
the gastrointestinal tract from injury have been recently
applied, including nitric oxide (NO) releasing NSAID
(NO-NSAID) (Takeuchi et al., 2001; Konturek et al.,
2003). The rationale behind this strategy is that NO
released from these derivatives exerts a beneficial
influence on gastric mucosa by enhancing the mucosal
defensive ability and preventing pathogenic events
resulting from suppression of PG synthesis such as a
reduction in gastric microcirculation and the leukocyte-
endothelial adherence. The major importance of NO in
the prevention of mucosal damage or in preservation of
ulcer healing is supported by previous studies showing
that NO exerts gastroprotective activity and accelerates
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healing mainly by the maintenance of blood flow around
the ulcer and the angiogenic process, by attenuation of
the oxidative injury and by compensation for PGs
deficiency induced by NSAID (Brzozowski et al., 2000,
2001b; Konturek et al., 2003).
L-Arginine (L-Arg) is available as a commercial
drug together with Ibuprofen to improve their
farmacokinetic characteristics. L-Arg, amino acid
precursor of NO, has shown its protective effects against
different experimental models of gastric lesions in rats
(Szlachcic et al., 2001; Ohta and Nishida 2001, 2002). In
previous studies, our group has observed the capacity of
L-Arg to attenuate the acute damage induced by the
NSAID Ibuprofen. This drug is considered a classical
NSAID with a similar capacity to inhibit both COX-1
and COX-2 enzymes and clinical data show a low
profile of gastrointestinal toxicity. The mechanism of the
beneficial response of the amino acid was associated
with a reduction of the oxidative response (Martín et al.,
2001; Jiménez et al., 2004) and also with a protective
effect mediated by COX/PG and NOS/NO/GMPc
pathways (Jiménez et al., 2002). 
The objective of the present study has been to
advance the knowledge of the gastric role played by the
amino acid L-Arg in the evolution and healing of a
chronic gastric ulcer. In order to clarify it, L-Arg alone
or together with Ibuprofen were administrated to the
ulcerated animals, by serosal application of acetic acid,
analysing characteristic parameters of an active curative
gastric process, such as PGE2 production, COX
expression, and also angiogenesis, proliferation/
apoptosis and growth factor expressions. 
Materials and methods
Animals
Male Wistar rats weighing 180-200 g (Service of
Animals, University of Seville, Spain) were used. The
rats were fed standard laboratory chow and tap water ad
libitum. The animals were deprived of food for 18-20
hours before experiments but had free access to water.
On the day of experimentation, all animals were
randomly assigned to one of several groups.
Experiments followed a protocol by the Ethical
Committee for Experimental Research of the Faculty of
Pharmacy of the University of Seville. All experiments
were in accordance with the recommendations of the
European Union.
Gastric ulcer induction
Chronic gastric ulcers were induced on day 0 using
20% acetic acid, according to the method described
previously with slight modifications (Motilva et al.,
1996). Fastened rats were anaesthetized by diethyl ether.
The abdomen was opened through a 2-cm laparatomy
incision and the stomach was exposed and, at the
junction of the corpus and antrum, 50 µl of 20% acetic
acid were injected with a micro syringe into the sub-
serosal layer of the anterior wall of the stomach. The
laparatomy incision was closed in two layers and the
animals recovered on a warmed mat with free access to
food and water. 
Twenty-four hours following ulcer induction, groups
of 14-16 rats were randomly allocated to receive one
unique dose of the three drugs (L-Arg, Ibuprofen and L-
Arg/Ibuprofen groups) or vehicle (control group) daily at
first hours in the morning, for 7 or 14 days. In sham
animals, the abdomen was opened and closed without
injection. 
Drugs and doses assayed
The dose administrated by Ibuprofen (Sigma
Chemical Co., Mo USA) in all treatments was 100
mg/kg body wt. A similar dose of oral L-Arg (Sigma
Chemical Co., Mo USA) plus Ibuprofen, each of them
100 mg/Kg body wt, was administered to another group
of rats (L-Arg/Ibuprofen group). A standard group that
received an orally similar dose of the amino acid alone,
100-mg/kg-body wt was introduced (L-Arg group). 
The drugs were dissolved in water and were
administered orally by gavages (1 ml/100 g body
weight). Sham groups received the vehicle in a
comparable volume. The doses were selected by
extrapolation of the clinical human doses and according
to studies previously performed in our group of
investigation (Jiménez et al., 2002; Sánchez-Fidalgo et
al., 2004).
Analysis of the damage and tissue sample collection
Rats were killed by ether anaesthetization twenty-
four hours after the late dose, and their stomachs were
excised. The stomachs were cut along its greater
curvature and the length and width of the gastric ulcer
was measured determining the lesion index, and the
degree of severity of the lesions was expressed as
percentage of the control group. 
Tissue from ulcer area including ulcer margin and
the remaining adjacent glandular mucosa -non ulcerated
area- were scraped with a glass slide on an ice-cold
glass, and frozen immediately in liquid nitrogen before
storage at -70 °C until they were used for Western blot,
PGE2 immunoassay and determination of apoptosis. 
For the histological study, gastric ulcers were
sampled at 7 and 14 days after ulcer induction and fixed
in 4% buffered formaldehyde. Small pieces obtained
from the stomach wall were dehydrated in cold with
shaking by means of a set of alcohols of increasing
concentration, from 50° until absolute alcohol. At the
end, the tissues were introduced successively in xylene,
xylene/paraffin 50%, finishing in paraffin at 60 °C. 24
hours later the blocks were formed and then sectioned
with a Leica Ultracut for immunohistochemical analysis.
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Western Blot Analysis of Cyclooxygenase Enzyme
Samples of the stomach were taken from all groups
treated and were homogenized in buffer containing
natrium vanadate and centrifuged at 10000 g, 10
minutes, 4 °C. The supernatant was collected and the
Bradford protein assay was carried out. 50 µg of protein
were separated on 8% acrylamide gel by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. In the next
step, the proteins were electrophoretically transferred to
a nitrocellulose membrane and probed with primary
antiserum to COX-1 and COX-2 at a final dilution of
1:2000 and 1:400 respectively. The secondary
horseradish peroxidase-linked donkey anti-goat
immunoglobulin G antibody (Santa Cruz Biotechnology,
CA) was used. Immunodetection was performed using
enhanced chemiluminescence. The signals were
analyzed and quantified by a Scientific Imaging Systems
(KODAK 1D Image Analysis Software).
Assessment of PGE2 formation
For measurement of COX activity, PGE2 wasdeterminate from gastric tissue samples obtained from
sham and control groups but also from gastric samples
of animals treated with different drugs. Briefly, gastric
mucosa was excised and rapidly rinsed with ice-cold
saline. The tissue was weighed and homogenized in 6 ml
TEAP buffer (pH 3.24) that contained a COX inhibitor,
Inyesprin®. The homogenate was centrifuged (3000 rpm,
10 min, 4 °C) and the supernatant was removed and
passed through a reverse-phase octadecylsilica C18 Sep
Pak cartridge which was washed with 10 ml distilled
water, 10 ml 15% ethanol, 10 ml hexane and 10 ml
ethylacetate, and the eluate collected. Each fraction with
ethylacetate was evaporated, and the dry residue re-
dissolved in ethanol. PGE2 was determined by a
competitive enzyme immunoassay kit (Cayman
chemical). Results are expressed as pg PGE2 /mg tissue.
Immunohistochemistry for vascular endothelial growth
factor (VEGF) and basic fibroblastic growth factor (FGF-
2)
Formalin-fixed and paraffin-embedded tissue
sections (5 µm) were dried in an oven at 55 °C for 1
hour and then deparaffinized in 2 changes of xylene and
hydrated from graded alcohols to water.
The staining of VEGF was carried out using a
Streptavidin-Biotin-Peroxidase method. A pressure-
cooking antigen retrieval system was used in which the
slides were boiled in 10 mM Tris (pH 10.0) at maximum
pressure for 1 min, followed by cooling at room
temperature for 20 minutes. The endogenous peroxidase
activity was inhibited and then the sections were
incubated in normal horse serum (Vectastain® Kit,
Vector Laboratories, Inc., Burlingame, CA) for 20 min to
reduce non-specific staining, and successively incubated
with monoclonal mouse anti-VEGF antibody
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(Oncogene™ Research Products) at dilution 1:20
overnight at 4 °C. Subsequently, slides were treated with
anti-mouse IgG antibody (Vectastain® Kit, Vector
Laboratories, Inc., Burlingame, CA) for 30 min and
incubated with the streptavidin-peroxidase complex
(Vectastain® Kit, Vector Laborartories, Inc., Burlingame,
CA) for 30 min, both steps at room temperature. 
The immunostaining of FGF-2 was carried out by
immunohistochemistry according to the Peroxidase-
Anti-Peroxidase (PAP) method. Previously, sections
were dipped in a solution of 3% hydrogen peroxide for
20 min at room temperature to inhibit endogenous
peroxidase activity. After washing in several changes of
phosphate buffered saline (PBS), the sections were
treated for 20 min with a protein blocking agent, 3%
bovine serum albumin in PBS, at room temperature to
block non-specific protein binding sites. Then they were
incubated at 4 °C overnight with the polyclonal rabbit
anti-FGF-2 antibody (Oncogene™ Research Products) at
dilution 1:20 in PBS. After rinsing in several changes of
PBS, the sections were transferred for 30 min to anti-
rabbit IgG antibody (Calbiochem®) diluted to 1:100 in
PBS at room temperature, rinsed in PBS and then were
incubated with rabbit PAP complex in the same
conditions. 
The enzymatic activities were developed with
3,3’–diaminobenzidine (DAB) and the sections were
counterstained with haematoxylin. Negative control
sections were treated in the same way omitting the
primary antibody. 
Results were classified as negative, few,
intermediate and high number of cells stained and
converted by a semi-quantitative scale into 0-3 arbitrary
units. Two investigators examined the scores
independently. In case of disagreement, a third
investigator also examined it. The final outcome was
expressed as percentage with respect to the control
group.
Determination of angiogenesis in the granulation tissue
The number of microvessels within chronic ulcer, as
an indicator of angiogenesis, was assessed by
immunohistochemical analysis for von Willebrand factor
(Weidner et al., 1991). The sections were digested with
0.1% trypsin (Difco laboratories, Detroit, MI) in distilled
water for 20 min at 37 °C. After inhibition of
endogenous peroxidase activity and non-specific protein
binding sites, the sections were incubated with the
primary antibody, polyclonal rabbit anti-human Factor
VIII-Related Antigen (DAKO Corporation, USA) for 1
hour at room temperature and the Streptavidin-Biotin-
Peroxidase method was used.
Individual microvessel counts were made. Any
positive cells or cell clusters that clearly were separate
from adjacent microvessels and other connective tissue
elements were considered single, countable
microvessels. Occasional immunopositive leukocytes
were excluded on morphologic grounds. The vascular
areas immediately adjacent to the normal tissue of the
stomach were not considered in the vessel counts.
However, these microvessels did serve as internal
quality controls for Factor VIII-RA immunostaining. In
all of the samples, the number of microvessels identified
from five microscopic fields in the ulcer base was
averaged. 
Immunohistochemistry for proliferating cell nuclear
antigen (PCNA) and apoptosis study
Mucosal cell proliferation was measured by
immunostaining for PCNA. Tissue was stained with an
anti-PCNA, which recognizes a nuclear antigen
expressed in all stages of the cell cycle. The basic
methodology used was the same as for VEGF. The
buffer used in the pressure-cooking antigen retrieval
system was citrate buffer (pH 6.0). Monoclonal mouse
anti-PCNA (DAKO) at dilution 1:1000 in PBS and anti-
mouse IgG antibody (Vectastain® Kit, Vector
Laboratories, Inc., Burlingame, CA) were used as
primary and secondary antibody.
For each ulcer, the PCNA-positive cells in the ulcer
margin and in the granulation tissue were counted as
defined by Yamada et al. (1992). The PCNA labelling
index (LI) was determined by calculating the ratio of the
number of positive cells to the total number of cells. A
cell was deemed to be positive only if it showed positive
nuclear staining. Three observers made the evaluations
independently.
Cytoplasmic DNA fragments, which are an indicator
of apoptosis, were measured with a DNA cell death
detection enzyme-linked immuno-sorbent assay (ELISA)
PLUS KIT (Roche Diagnostics). The assay is based on a
quantitative sandwich-enzyme-immunoassay-principle
using mouse monoclonal antibodies directed against
DNA and histones, respectively. This allows the specific
determination of mono-and oligonucleosomes in the
cytoplasmic fraction of cell lysates. The values are
expressed as mU/g tissue (mU=absorbance [10-3]).
Statistical analysis 
The results are expressed as mean ± SEM. Statistical
comparisons were evaluated by one-way analysis of
variance (ANOVA test) followed by Bonferoni test.
Statistical analysis was performed using GraphPad Prism
2.01. Values of probability p<0.05 were considered
significant.
Results
Effect of L-Arginine on the healing of the chronic gastric
ulcer
Figure 1A shows the percentage of damage versus
control group at 7 or 14 days of the different treatments
in the acetic acid model followed. 
Well-defined ulcers were developed in the corpus
mucosa 7 and 14 days after application of acetic acid. In
the Ibuprofen group the healing of the gastric ulcers was
impaired, especially at 14 days, which was significant
with respect to the control group (p<0.01). On the
contrary, L-Arg administration at the same time as that
Ibuprofen resulted in an important reduction of ulcer
index calculated at 7 days (p<0.05 vs. control). On day
14, the presence of the amino acid reduced the gross
appearances of acetic acid ulcers observed with the
Ibuprofen group (p<0.05), and the result was closer to
control-14 days group.
The histological study was carried out at 14 days
because this is time enough to observe a significant
recuperation of the lesions. In this time, some epithelial
cells in the ulcer margin further proliferate and migrate
over and into the ulcer crater, which was strongly
infiltrated by inflammatory cells, fibroblasts and
endothelial cells. Necrotic tissue was also present at this
stage, whereas the gastric mucosa around the ulcer crater
remained unchanged (Fig. 1B). The muscularis mucosae
around the ulcer margin was replaced by a granulation
tissue. An interesting increase of the thickness of the
granulation tissue of the ulcer bed with abundant density
of new vessels developing in this area, but also in the
submucosa adjacent to the ulcer crater, were strongly
detected after treatment with L-Arg (Fig. 1C). 
Effect of L-Arginine on cyclooxygenase expression and
release of prostaglandins in the evolution of lesions 
We examined the expression of COX-1 and COX-2
protein in gastric tissues by the western-blotting method.
No variations in COX-1 expression were observed in
samples obtained from sham, ulcerated and non-
ulcerated gastric mucosa without or with treatment (data
not shown). However, COX-2 protein expression was
increased and detectable at 7 days in the ulcer area (Fig.
2) (p<0.05 vs. sham and non ulcerated area of control
groups), although this production was disappearing on
time and on day 14 no significant protein expressions
were found in any group assayed (data not shown). The
treatment with Ibuprofen increased this expression in the
samples from ulcerated area and detected in the 7-days
period (p<0.01 vs. ulcerated control group). The signal
of COX-2 expression analysed after L-Arg/Ibuprofen
administration was significantly less than that from
Ibuprofen group (p<0.05).
PGE2 levels in control and treated groups of both
periods (7 and 14 days) and measured in tissue from
ulcerated areas and also from areas not damaged are
shown in figure 3A and B. At day 7, PGE2 control group
production augmented significantly in tissues proceeding
from ulcerated areas (p<0.001). Ulcer samples from
animals administrated with L-Arg, Ibuprofen and
Ibuprofen/L-Arg treatments showed significant
reduction of PGE2 content (p<0.001) (Fig. 3A). At the
14 day period, PGE2 production also was augmented in
the ulcerated area of the control group (p<0.01) (Fig.
3B). However, only after Ibuprofen treatment the
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prostanoid production was significantly inhibited as
demonstrated by the results of samples from ulcerated
(p<0.05); The presence of L-Arg limited this inhibition,
and the PGE2 levels were close to that observed in the
control group (Fig. 3B).
Effect of L-arginine on VEGF and FGF-2 expression and
angiogenesis in chronic gastric ulcers
The final outcome of the healing process is a
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Fig. 2. Effects of amino acid L-Arginine on
COX-2 protein expression in acetic acid gastric
ulcer after 7 days of ulcer induction. Gastric
ulcers were induced by 50 µl of 20% acetic
acid. Every day the animals were treated with
vehicle (control group), L-Arginine (Arg, 100
mg/kg body wt), Ibuprofen (Ibu, 100 mg/kg
body wt), or L-Arginine with Ibuprofen (Ibu/arg,
each of them 100 mg/kg body wt), in a unique
dose. In sham animals, the abdomen was
opened and closed without injection. Tissue
from ulcer and non ulcerated area of animals
of each group were obtained for western blot
analysis. Samples were separated on
acrylamide by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, transferred
to a nitrocellulose membrane and probed first
with anti-COX-2 antibody. A representative blot
and the results of densitometry analysis 4 rats
per group (expressed in arbitrary units) are
shown. Data are expressed as the mean ±
SEM of number of animals. * p<0.05 ** p<0.01
and *** p<0.001 vs. sham and non ulcerated
control group; ++ p<0.01 vs. ulcerated control
group; # p<0.05 vs Ibuprofen group.
Fig. 1. Effect
of amino
acid L-
Arginine on
healing of
chronic
gastric
acetic ulcer.
Gastric
ulcers were
caused by
50 µl of 20%
acetic acid.
Every day
the animals
were treated
with vehicle
(control group), L-Arginine (Arg, 100mg/kg body wt), Ibuprofen (Ibu, 100mg/kg body wt), or L-Arginine with Ibuprofen (Ibu/arg, each of them 100mg/kg
body wt), in a unique dose. In sham animals, the abdomen was opened and closed without injection. After 7 and 14 days the animals were killed and
the degree of severity of the lesions was expressed as percentage of the control group (A). Values are mean ± SEM of 14-16 rats per group. * p<0.05
and ** p<0.01 vs. control group; + p<0.05 vs. Ibuprofen group. The histological study showed a significant recuperation of the lesions. Epithelial cells in
the ulcer margin further proliferate and migrate over and into the ulcer crater, which were strongly infiltrated by inflammatory cells, fibroblasts and
endothelial cells. Necrotic tissue was also present at this stage, whereas the gastric mucosa around the ulcer crater remained unchanged (B). New
vessels developing in granulation tissue were strongly detected after treatment with L-Arginine (C).
dynamic interaction between the epithelial component
from the healing zone at the ulcer margin and the
connective tissue component (including microvessels),
originating from granulation tissue, with special
regulation by FGF-2 and VEGF (Tarnawski et al., 2001).
Immunohistochemical studies revealed that VEGF
protein, specially expressed in the granulation tissue of
control rats and observed in granulocytes, fibroblasts,
and smooth muscle, was not modified between the
different groups of animals treated (Figs. 4, 5). 
The immunoreactivity for FGF-2, detected in
regenerative areas of the ulcer margin and in the
granulation tissue of the ulcer bed, was also markedly
increased. This protein was located in most of the typical
fibroblasty cells, granulocytes and smooth muscle cells
in the ulcer crater, granulation tissue, and in the stromal
cells in the lamina propia on the ulcer margin. This
immunopositivity for FGF-2 was especially significant
in groups that received L-Arg (p<0.001) (Figs. 4 , 5).
Endothelial cells were stained with FVIII antibody
in order to detect the growth of new blood vessels. Their
density was higher at the granulation tissue from animals
treated with L-Arg (Fig. 6). The Ibuprofen group at the
time analysed did not modify the number of
microvessels with respect to control group. 
Effect of L-Arginine on proliferation and apoptosis in
chronic gastric ulcers
To investigate the effect of L-Arg on proliferation in
chronic gastric ulcers, this cell process was quantified by
immunostaining. The immunoreaction for PCNA was
observed as a dark accumulation of DAB reaction
products in the nuclei of the middle and lower parts of
the cript in the normal gastric mucosa. In the control
ulcerated group, PCNA-positive were augmented respect
to sham and distributed in epithelial cells of the ulcer
margin and in fibroblastic cells of granulation tissue.
Neither treatment modified significantly this parameter
with respect to the control group (Fig. 7). 
Because gastric mucosal inflammations contribute to
cell turnover, we investigated whether apoptosis is
altered by chronic gastric ulcers and how these apoptotic
effects are affected by L-Arg. In table 1 it can be
observed that the apoptotic effect is augmented after
acetic acid application and none of the assayed treatment
modified it. 
Discussion
In this study, we examined the role of the amino acid
L-Arg in the evolution of the healing process of a
chronic gastric ulcer induced by acetic acid and in
presence of equal doses of ibuprofen, a classical NSAID
COX-1 and COX-2 inhibitor. 
Inhibition of COX-1, and the consecutive reduction
of PGs and tromboxanes (TX), explained the
pharmacological activity of NSAID, but also the side
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Fig. 3. Effects of amino acid L-Arginine on PGE2 accumulation in
chronic gastric ulcers after 7 days (A) and 14 days (B). Gastric ulcers
were induced by 50 µl of 20% acetic acid. Every day the animals were
treated with vehicle (control group), L-Arginine (Arg, 100 mg/kg body
wt), Ibuprofen (Ibu, 100 mg/kg body wt), or L-Arginine with Ibuprofen
(Ibu/arg, each of them 100 mg/kg body wt), in a unique dose. In sham
animals, the abdomen was opened and closed without injection. Tissue
from ulcer and non ulcerated area of animals of each group were
obtained. PGE2 level was determined by a competitive enzyme
immunoassay kit. Values are mean ± SEM of 10 rats. ** p<0.01 and ***
p<0.001 vs. sham and non ulcerated control group; + p<0.05 and +++
p<0.001 vs. control group in the same area.
Fig. 4. Effect of amino acid L-Arginine on basic fibroblast growth factor
(FGF-2) and vascular endothelial growth factor (VEGF) expression in
chronic gastric ulcer after 14 days. The immunostainings for FGF-2 and
VEGF were carried out by immunohistochemistry according to the
Peroxidase-Anti-Peroxidase (PAP) and Streptavidin-Biotin-Peroxidase
method, respectively. The immunostaining was converted by a
semiquantitative scale into 0-3 arbitrary units. Data are expressed as
the mean ± SEM of number of animals. *** P<0.001 vs control and
Ibuprofen group.
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Fig. 5. Effect of amino acid L-Arginine on the immunohistochemical staining of basic fibroblast growth factor (FGF-2) and vascular endothelial growth
factor (VEGF) expression in chronic gastric ulcer after 14 days. The immunostainings for FGF-2 and VEGF were carried out by immunohistochemistry
according to the Peroxidase-Anti-Peroxidase (PAP) and Streptavidin-Biotin-Peroxidase method, respectively. FGF-2 expression in control group (A), in
L-Arginine group (B), in Ibuprofen group (C) and L-Arginine with Ibuprofen group (D). VEGF expression in control group (E), in L-Arginine group (F), in
Ibuprofen group (G) and L-Arginine with Ibuprofen group (H). Original magnification x 400 and x 200, respectively.
effects associated and especially gastrointestinal
ulceration. The discovery of a new isoform, the COX-2,
amplified the hypothesis: the constitutive expressed
COX-1 is the housekeeping enzyme responsible for
physiological activities of PG, while COX-2, whose
expression is induced under inflammatory conditions, is
responsible for pathological PGs (Crofford, 1997).
However, after clinical use, the COX-2 hypothesis
turned out to be more complicated than initially thought.
Both enzymes have physiological and pathological roles,
and COX-2 inhibitors, which improved safety profile in
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Fig. 7. Effects of L-Arginine on Proliferating Cell Nuclear Antigen (PCNA) in chronic
gastric ulcers after 14 days. The PCNA-positive cells were identified by
immunohistochemistry according to the Streptavidin-Biotin-Peroxidase method.
Immunoreactions for PCNA were observed as a dark accumulation of DAB reaction
products in the nuclei of cells in ulcer margin and granulation tissue. PCNA
expression in control group (A), in L-Arginine group (B), in Ibuprofen group (C) and
L-Arginine with Ibuprofen group (D). Original magnification x 200
Fig. 6. Effect of amino acid L-Arginine on angiogenesis in chronic
gastric ulcers after 14 days. The microvessels were identified by an
immunohistochemical method for von Willebrand factor according to the
Streptavidin-Biotin-Peroxidase method. The number of microvessels
was obtained from five microscopic fields in the ulcer base at x 200 and
magnification was averaged (A). Von Willebrand factor expression in L-
Arginine with Ibuprofen group (B). Data are expressed as the mean ±
SEM of number of animals. ** P<0.01 vs control group.
healthy gastrointestinal mucosa, worsen and complicate
pre-existing ulcers, and may induce cardiovascular or
renal side-effects (Bombardier et al., 2000; Brzozowski
et al., 2001a; Berenguer et al., 2002; Sánchez-Fidalgo et
al., 2004). 
An alternative approach aimed at obtaining safer
NSAID is based on the gastroprotective effects of NO.
In the stomach, NO plays many important roles
including regulation of microcirculation, gastric motility,
or mucus and acid secretion (Fisorucci and del Soldato,
2003; Coruzzi et al., 2004; Wallace et al., 2004).
Classical NSAID chemically linked to NO-releasing
moieties retain the therapeutic efficacy, but not the
adverse effects of the parent NSAIDs. On the other hand,
NO-NSAID are a highly promising novel class of drugs
that may impact several areas of therapeutics and data
from different studies indicate that NO-NSAID could be
effective in a variety of diseases (del Soldato et al.,
1999; Keble and Moore, 2002; Yeh et al., 2004). 
L-Arg is a basic amino acid that plays several
pivotal roles in cellular physiology. Like any amino acid,
it is involved with protein synthesis, but it is also
intimately involved with cell signalling through the
production of NO. L-Arg has demonstrated its regulative
capacity of inflammatory responses by precursor for
production of the NO but also for pro-proliferative
polyamines (Satriano, 2003). 
The results from the present study reveal that L-Arg
is favourable in the healing process improving the
curative course. Ibuprofen alone caused a delay in ulcer
healing, more evident 14 days after ulcer induction; The
expression of COX-2 was increased on the 7th day
although no signal of protein could be detected after 14
days; PGE2 production was inhibited by the NSAID in
intact areas of mucosa as well as in tissue from the
ulcerated areas at both times assayed. In contrast,
treatment with L-Arg reduced the delay of the lesion, the
increment in COX-2 expression induced by Ibuprofen
was attenuated, and samples taken after 14 days of ulcer
induction showed that L-Arg was able to maintain PGE2
levels similar to the control group. 
Early work showed that L-Arg exerts a protective
role in different acute models of experimental gastric
damage such as stress, ethanol, or pylorus ligation (Dixit
et al., 1999; Nishida et al., 1999; Kalia et al., 2000;
Szlachcic et al., 2001; Ohta and Nishida, 2002) and also
in chronic gastric studies (Brzozowski et al., 1997). The
information obtained concerned NO produced by L-Arg
in the vasodilatation and enhancement in mucosal barrier
activity (Byrne et al., 1997; Calatayud et al., 1999)
although endogenous PGs have also been implicated
(Brzozowski et al., 1993; Jiménez et al., 2002). In this
line, our group have observed that the mechanism of the
protective effect of L-Arg could be explained in different
forms although the COX/PG pathway and the NO
liberated by a NOS/cGMP pathway were decisive
(Jimenez et al., 2002). The present study confirms the
favourable effect of L-Arg in the regulation of COX
activity, not on its expression, increasing the levels of
PGE2 up to 14 days after ulcer induction with Ibuprofen
presence. The connection between NOS and COX ways
may be considered, although contradictory results have
been reported (Paya et al., 1997; Brock et al., 2003; Uno
et al., 2004). Chemical reactivity of NO would affect
both conformation and activity of the COX enzyme; an
attack to the COX enzyme directly through the
coordination to heme-iron in the prosthetic group of the
enzyme, or the reaction with tyrosyl radical located in
the active site (Gunther et al., 1997; Salvemini, 1997)
although the influences to supply COX substrate have
been also proposed (Ma et al., 1996). 
Additionally, the histological study showed that the
healing effects of L-Arg might be associated with an
increased angiogenesis and an augmented expression of
the FGF-2. These actions could be considered key
factors in the healing response associated with L-Arg
administration. However, the proliferation study assayed
with the PCNA-immunostaining method did not reveal
significant differences, neither did the apoptosis
analysis. 
Growth factors regulate cell proliferation and also
mediate processes such as extracellular matrix
formation, cell migration and differentiation, immune
regulation, and tissue remodelling (Menard, 2004). In
the digestive mucosa, different factors, such as EGF,
PDGF, FGF-2, or VEGF, have demonstrated their
capacity to accelerate the healing process through the
stimulation of angiogenesis, cell proliferation and
migration of gastric mucosal cells during the ulcer
healing process (Szabo and Vincze, 2000; Tarnawski et
al., 2001). 
Our results from the immunohistochemical study
showed that L-Arg markedly increased the FGF-2
expression and also the angiogenic process in areas of
active damage and restoration. These changes were also
regulated even in the presence of Ibuprofen.
Nevertheless, no variations could be observed in the
VEGF expression at this time. These responses are in
line with previous studies where the angiogenesis
promoted by L-Arg changed in parallel with nitric oxide
synthase expression and activity (Brzozowski et al.,
1997; Ma and Wallace, 2000). The acceleration of ulcer
healing is through mucosal nitric oxide and FGF-2-
associated integrated pathways and followed by an
increase of angiogenesis and mucosal regeneration (Li
and Cho, 1999). However, other explanations must be
analysed and based on arginine metabolism. Satriano
(2003) proposes that arginine is the precursor for
production of NO and the pro-proliferative polymines,
the NO being a key factor in the early phase response,
whereas the increased generation of polyamines is
requisite for the later repair phase response. The
possibility of a third pathway is analyzed where the
metabolism of arginine to agmatine by a decarboxylase
may have the potential to serve as coordination of the
early or later repair pathways in inflammation.
Obviously, further studies are necessary for a better
understanding of the exact role played by L-Arg in this
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process.
In conclusion, the coupling of L-Arg to Ibuprofen is
an attractive alternative to Ibuprofen administration
alone because it not only attenuates but also improves
the evolution of chronic lesions through mechanisms
that implicate endogenous PG and FGF-2-associated
pathways, which allow an increase of the angiogenic
process. These studies support the notion of the potential
importance played by the amino-acid in different
physiological and pathological processes including
inflammation. 
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